[The role of drug Cytoflavin in the correction of dysautonomia in patients with post-COVID syndrome].

Objective: To evaluate the autonomic dysfunction of cardiovascular system (CVS) in patients with post-COVID syndrome with the help of active orthotest and heart rate variability methods.

Material And Methods: 70 patients with PCOS were examined, who were divided into 2 groups. Group 1 patients received standard therapy and Cytoflavin for 35 days, Group 2 patients received only standard therapy.

[The successful use of Cytoflavin in the patient with postaveny syndrome].

A clinical observation of the use of Cytoflavin according to a two-stage scheme (10.0 ml intravenously drip per 200 ml of 0.9% sodium chloride solution for 10 days, followed by a transition to a tablet form of 2 tablets 2 times/day for 25 days) in a patient with postcovid syndrome with pronounced vegetative and neurocognitive disorders.

Assessment of Hearing and Vestibular Functions in a Post-COVID-19 Patient: A Clinical Case Study.

SARS-CoV-2 infection may cause such complications as post-COVID-19 syndrome, which includes chronic fatigue, myalgia, arthralgia, as well as a variety of neurological manifestations, e.g., neuropathy of small fibers, hearing and vestibular dysfunction, and cognitive impairment.

Intravenouse immunoglobuline in dysautonomia.

Nowadays intravenous immunoglobulin (IVIg) treatment is considered to play a promising role in the autoimmune disease therapy. Despite its significant beneficial effects, the precise mechanism of action needs further studies, as well as recommended dosage in the treatment of autoimmune dysautonomia. In some diseases, like Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating neuropathy (CIDP), IVIg has a strong evidence that allows to recommend and prescribe the medication, while in other diseases only single case studies are available that requires further research.